Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design

Annu Rev Immunol. 2016 May 20;34:635-59. doi: 10.1146/annurev-immunol-041015-055515.

Abstract

HIV employs multiple means to evade the humoral immune response, particularly the elicitation of and recognition by broadly neutralizing antibodies (bnAbs). Such antibodies can act antivirally against a wide spectrum of viruses by targeting relatively conserved regions on the surface HIV envelope trimer spike. Elicitation of and recognition by bnAbs are hindered by the arrangement of spikes on virions and the relatively difficult access to bnAb epitopes on spikes, including the proximity of variable regions and a high density of glycans. Yet, in a small proportion of HIV-infected individuals, potent bnAb responses do develop, and isolation of the corresponding monoclonal antibodies has been facilitated by identification of favorable donors with potent bnAb sera and by development of improved methods for human antibody generation. Molecular studies of recombinant Env trimers, alone and in interaction with bnAbs, are providing new insights that are fueling the development and testing of promising immunogens aimed at the elicitation of bnAbs.

Keywords: conserved epitopes; immunization strategies; passive immunotherapy; rational vaccine design; vaccination.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / immunology*
  • Animals
  • Antibodies, Neutralizing / metabolism*
  • Conserved Sequence
  • HIV / immunology*
  • HIV Antibodies / metabolism*
  • HIV Infections / immunology*
  • HIV Infections / prevention & control
  • Humans
  • Immune Evasion
  • Immunization, Passive / methods*
  • Immunization, Passive / trends
  • Viral Envelope Proteins / immunology
  • Virion / immunology*

Substances

  • AIDS Vaccines
  • Antibodies, Neutralizing
  • HIV Antibodies
  • Viral Envelope Proteins